Cancer occurrence in Turner syndrome and the effect of sex hormone substitution therapy.


Journal

European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 24 06 2020
accepted: 14 10 2020
pubmed: 29 10 2020
medline: 15 12 2020
entrez: 28 10 2020
Statut: ppublish

Résumé

Although the overall risk of cancer is not increased in Turner syndrome, the pattern of cancer occurrence differs from the general population. We aim to describe the cancer morbidity pattern in Turner syndrome and evaluate the effect of long-term hormone replacement therapy (HRT). Nationwide epidemiological study. 1156 females with Turner syndrome diagnosed during 1960-2014, were linked with data from the Danish National Patient Registry. Statistics Denmark randomly identified 115 578 female controls. Stratified Cox regression was used to analyze cancer morbidity, mortality and effect of HRT. Overall risk of cancer was not elevated (hazard ratio 1.04 (95% CI: 0.80-1.36)). The risk of skin cancer and benign skin neoplasms was two-fold increased, while the risk of breast cancer was decreased (hazard ratio 0.4 (0.2-0.9)). Turner syndrome (45,X) had a two- to five-fold increased risk of benign CNS tumors, colon and rectal cancers, benign skin neoplasms and skin cancer. Turner syndrome women with a 45,X/46,XX karyotype had an increased risk of tongue cancer. HRT had no impact on the risk of any cancer investigated in this study. The lack of one X chromosome might play a role in skin neoplasms, CNS tumors, colon and rectal cancers. The risk of breast cancer is lower than in the general population. Long-term HRT during the premenopausal age range seems not to exert a cancerous effect in Turner syndrome. Increased vigilance concerning specific types of cancer in Tuner syndrome harboring a 45,X karyotype is needed.

Identifiants

pubmed: 33112259
doi: 10.1530/EJE-20-0702
pii: EJE-20-0702
doi:
pii:

Substances chimiques

Gonadal Steroid Hormones 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

79-88

Auteurs

Mette Hansen Viuff (MH)

Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Department of Internal Medicine and Endocrinology, Aarhus University Hospital, Aarhus, Denmark.

Kirstine Stochholm (K)

Department of Internal Medicine and Endocrinology, Aarhus University Hospital, Aarhus, Denmark.

Angela Lin (A)

Medical Genetics Unit, Massachusetts General Hospital for Children, Boston, Massachusetts, USA.

Agnethe Berglund (A)

Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Department of Internal Medicine and Endocrinology, Aarhus University Hospital, Aarhus, Denmark.
Department of Clinical Genetics, Aarhus University, Aarhus, Denmark.

Svend Juul (S)

Department of Public Health, Aarhus University, Aarhus, Denmark.

Claus Højbjerg Gravholt (CH)

Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Department of Internal Medicine and Endocrinology, Aarhus University Hospital, Aarhus, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH